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Abstract
Metformin, a Type II diabetic treatment drug, which inhibits transcription of gluconeogenesis genes, has recently been
shown to lower the risk of some diabetes-related tumors, including breast cancer. Recently, ‘‘cancer stem cells’’ have been
demonstrated to sustain the growth of tumors and are resistant to therapy. To test the hypothesis that metformin might be
reducing the risk to breast cancers, the human breast carcinoma cell line, MCF-7, grown in 3-dimensional mammospheres
which represent human breast cancer stem cell population, were treated with various known and suspected breast cancer
chemicals with and without non-cytotoxic concentrations of metformin. Using OCT4 expression as a marker for the cancer
stem cells, the number and size were measured in these cells. Results demonstrated that TCDD (100 nM) and bisphenol A
(10 mM) increased the number and size of the mammospheres, as did estrogen (10 nM E2). By monitoring a cancer stem cell
marker, OCT4, the stimulation by these chemicals was correlated with the increased expression of OCT4. On the other hand,
metformin at 1 and 10 mM concentration dramatically reduced the size and number of mammospheres. Results also
demonstrated the metformin reduced the expression of OCT4 in E2 & TCDD mammospheres but not in the bisphenol A
mammospheres, suggesting different mechanisms of action of the bisphenol A on human breast carcinoma cells. In
addition, these results support the use of 3-dimensional human breast cancer stem cells as a means to screen for potential
human breast tumor promoters and breast chemopreventive and chemotherapeutic agents.
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Introduction
Metformin, a Type 2 diabetic treatment drug, which inhibits
transcription of gluconeogenesis genes [1], has recently been
shown to lower the risk of some diabetes-related tumors, including
breast cancer [2–15]. However, not all studies demonstrate this
response [2] possibly due to confounding factors. Although
patients with diabetes are at high risk for cancers of the liver,
pancreas, endometrium, breast, colon, and bladder, it is not clear
as to whether the positive effects of metformin against certain
cancers affects the cancer, directly or indirectly, by inhibiting the
diabetic state. In addition, it is not clear whether metformin might
affect other cancers in non-diabetic individuals. Moreover,
metformin inhibited the growth of breast cancer cell lines in vitro.
However, in some cases, it inhibited non-transformed cells at
similar concentrations [16–18].
Recently, it has been demonstrated that ‘‘cancer stem cells’’
sustain the growth of tumors and are resistant to therapy. MCF-7
mammospheres have been shown to enrich breast cancer stem cells
expressing CD44
+CD24
2/low [19,20]. Assuming the concept of
‘‘cancer stem cells’’ as the ‘‘tumor-initiating’’ or ‘‘tumor-sustaining’’
cells of any tumor or permanent cell line [21–23], the objective of
this study was to determine the effects of several known epigenetic-
acting chemicals, such as endocrine disrupting- or tumor promoting
chemicals (phenol red [24], TCDD [25,26] and bisphenol A [27]),
compared to estrogen’s effect on the growth of MCF-7 mammo-
spheres. These chemical –treated mammospheres were exposed to
metformin at various non-cytotoxic concentrations. In effect, this
series of experiments was designed to test the hypothesis that
metformin might be reducing the risk to certain cancers by affecting
the breast cancer stem cells in these mammospheres.
The results, in general, demonstrated that metformin reduced
the expression of Oct4 in E2- and TCDD- treated human breast
cancer stem cells in MCF-7 mammospheres, but not in the
bisphenol A-treated mammospheres, suggesting a different
mechanism of action of the bisphenol A on the breast cancer
stem cells self-renewal ability. In addition, the study supports the
use of 3-dimensional mammospheres to screen for potential
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e28068human breast tumor promoters or cancer chemopreventive or
chemotherapeutic agents.
Results
The mammosphere formations of human breast cell lines
The mammospheres were generated from the ERa positive
human breast cancer cell line, MCF-7, M13SV1, M13SV1 R2
and M13SV1 R2N1, in phenol red-containing MEBM and phenol
red-free MEBM. In both media, the cells efficiently formed
compact mammospheres (Figure 1). MCF-7 cells were continu-
ously capable of forming mammospheres through repeated
subcultures in medium with phenol red (data not shown). ER-
negative human breast cancer cell lines, MDA-MB-231 cells
(Figure 1E) and SK-BR-3 cells (data not shown), failed to form
mammospheres in both phenol red-contained MEBM and phenol
red-free MEBM. Rather, they formed aggregated clusters of cells.
It suggests that the estrogen receptor status of breast cells affected
the formation and maintenance of mammospheres.
Flow cytometric analysis of MCF-7 mammospheres
As stated above, MCF-7 cells efficiently formed mammospheres
and this ability was maintained through repeated subcultures in
phenol red-contained media. To identify the relationship of
mammosphere formation and cancer stem cell population, we
carried out flow cytometry using the cancer stem cell markers
(CD44
+/ CD24
2/low) [28]. The results indicated that secondary
mammospheres consisted of 0.1% (through side scatter; P1) and
2.7% (through forward scatter; P2) mammary stem cell popula-
tion, while tertiary mammospheres had 1.1% (P1) and 15.9% (P2).
Indeed, as mammospheres were passaged, cancer stem cell
populations were increased. The mRNA expression of OCT4
gene was up-regulated in tertiary mammospheres compared to
secondary mammospheres (Figure 1I).
OCT4 expression induced by phenol red in
mammospheres
Phenol red has been shown to act as a weak estrogens in ER-
positive MCF-7 cell line [24]. In order to examine the effects of
phenol red on the stemness of ER-positive human mammospheres
(MCF-7, M13SV1, M13SV1 R2, M13SV1 R2N1), we measured
the cancer stem cell marker, OCT4 gene expression, in mammo-
spheres cultured in phenol red-free or phenol red-containing
MEBM. In most cases, where the mammospheres were cultured in
phenol red-free MEBM, OCT4 gene expression was significantly
decreased compared to phenol red-containing medium (Figure 1J).
Therefore, it was suggested that estrogenicity does have a role in
OCT4 expression in ER-responsive human breast cells.
17-beta-estradiol induced OCT4 expression in MCF-7
mammospheres
To identify the direct relationship between mammosphere
formation and estrogen, we treated of 17-beta-estradiol (E2) in
MCF-7 mammospheres (1 nM to 1000 nM). Mammospheres of
the biggest size and of the largest in number were observed at 10
nM concentration of E2 (Figures 2A, B). Interestingly, the highest
level of OCT4 expression was observed at 10 nM concentration of
E2 (Figure 2C) as well. Therefore, 10 to 20 nM concentration of
E2 could induce dramatic increase of OCT4 expression and
proliferation of mammospheres, as well as the breast cancer stem
cell population in MCF-7 mammospheres.
ER antagonist inhibits estrogen-induced mammosphere
formation and OCT4 expression
To confirm whether the above-mentioned effect of estrogen was
ER dependent, we treated the MCF-7 cells with the ER alpha
antagonist, ICI 182,780, along with 17-beta-estradiol. The results
showed that the size and number of mammospheres were
Figure 1. ER positive (A–D and F–H) and negative (E) human breast cells in phenol red-contained (A–E) or phenol red-free MEBM (F–
H), expression level of OCT4 mRNA in passaged MCF-7 mammospheres (I), and several ER+ breast cancer mammospheres cultured
in MEBM with or without phenol red (J). ; (A) MCF-7; (B), (F) M13SV1; (C), (G) M13SV1 R2; (D), (H) M13SV1 R2N1; (E) MDA-MB-231. The
magnification was X 200. Scale bar represents 50 mm in length.
doi:10.1371/journal.pone.0028068.g001
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ICI 182,780 (Figures 3A, B). Interestingly, these inhibitory effects
of ER alpha antagonist occurred, not only on mammosphere
formation, but also on OCT4 expression. ICI 182,780 repressed
OCT4 induction by estrogen (Figures 3C, D). These results suggest
that low concentration E2 (1–20 nM) might up-regulate OCT4
expression through an ER-dependent pathway.
Effect of the antioxidant in high concentration of E2
Estrogen was reported to induce reactive oxygen species (ROS)
production in high concentration [29,30]. MCF-7 mammospheres
were treated with N-acetyl-L-cysteine (NAC), 10 mM with high
concentration E2 (100 nM). Interestingly, NAC increased the size,
number of primary mammospheres and reduced the ROS production
levels (Figures 4A, B). Moreover, the number of secondary mammo-
spheres was increased (Figure 4C). These results might suggest 10 mM
NAC blocks E2-induced oxidative stress and subsequent cell damage
to increase proliferation and symmetrical cell division of the OCT4
positive cancer stem cells in MCF-7 mammospheres.
Regulation of mammosphere formation by breast cancer
promoters and metformin
To know whether tumor promoting agents effect mammosphere
formation, we used TCDD and BPA, both estrogenic disrupting
chemicals, on MCF-7 mammosphere. On the other hand,
metformin, an antidiabetic drug with anticancer effects against
various diabetes-associated cancers, including breast cancer
[3,6,31], was tested for regulation of mammosphere formation.
MTT assay showed that TCDD increased MCF-7 cell prolifer-
ation in a dose dependent manner (Figure 5A upper), yet, the
effect was lower than that of E2. BPA also increased MCF-7 cell
proliferation up to 10 mM, however the increase was not
statistically significant (Figure 5A middle). Metformin decreased
MCF-7 cell growth at the 1 mM and 10 mM concentrations
(Figure 5A lower). Lower doses of metformin than 1 mM did not
show significant decrease in cell proliferation. To confirm the
potential cytotoxicity, MTT assay was conducted only after a 24 h
treatment. MCF-7 cells exhibited cytotoxicity at higher concen-
trations of BPA (.100 mM) but did not show cytotoxicity at
10 mM metformin (Figure S1).While the in vitro concentrations
were higher than what is normally found in vivo, due to the
complexity of in vitro-in vivo extrapolations [32], and the fact that
the in vitro mammospheres were not vascularized, this difference
might not be unexpected. Based on these results, we chose the 100
nM of TCDD and 10 mM of BPA, in which MCF-7 showed
maximal enhancement of cell proliferation. In addition, 1 mM
and 10 mM metformin were chosen for their inhibitory effects on
MCF-7 cell growth. Efficiency of MCF-7 mammosphere forma-
tion was assessed after treatment of E2, TCDD or BPA with or
without metformin treatment. As a result, the treatment of E2,
TCDD and BPA without metformin increased the size of MCF-7
mammosphere (Figure 5B). Addition of the metformin exhibited
reduction in sphere size. The numbers of mammospheres were
significantly increased by treatment of the E2 and TCDD and
metformin decreased the number of MCF-7 mammosphere in a
dose dependent fashion (Figure 5C).
The Control of ERE at the promoter region of OCT4
We checked the OCT4 expression level after treatment of E2,
TCDD or BPA with or without metformin (Figure 6A). Interest-
ingly, E2- and TCDD- treated cells, without metformin, showed
increased expression level of OCT4, however, BPA did not. In
addition, metformin blocked the enhancement of OCT4 expression
caused by treatment of E2 or TCDD in MCF-7 cells. On the other
hand, BPA treatment in MCF-7 cells did not increase OCT4
expression. To identify the role of estrogen signaling on OCT4
expression regulation, we searched estrogen binding elements
(EREs) in the promoter region of OCT4 gene. EREs are ER
binding site highly conserved in several species [33]. Common
ERE sequences (59 – GGTCAnnnTGACC – 39) are well known,
and slight variations are acceptable [33]. We looked for common
ERE sequences at the OCT4 promoter region, which ranges from
5 kb upstream to 5 kb downstream of transcription starting site,
however, there was no identical sequences. We then screened
sequences which have minor variation on 1 to 3 nucleotides.
There were 4 ERE target sequence with minor sequence
variations at OCT4 promoter region (Figure 6B and Table S2).
To identify whether the putative ERE binding sites are bound by
ER, we performed ChIP assay (Figure 6C). pS2, which has well
known ERE target sequence, was used as positive control. ChIP
assay showed that binding of ER to a putative ERE binding site at
-3544 kb of OCT4 transcription start site was enriched after
treatment of E2 with similar level to that of pS2. Another putative
binding site at +4763 kb showed a slight increase of ER binding,
however, the enhancement of binding level was negligible. To
confirm whether breast cancer promoting and inhibiting chemi-
cals, we tried ChIP assay with treatment of TCDD, BPA and
metformin in MCF-7 cells (Figure 6D). The binding of ER at
Figure 2. Effect of E2 on MCF-7 mammospheres. (A), (B)
Mammosphere formation was increased by 10 nM E2 treatment. Data
were presented as the number of mammospheres per 1,000 seeded
cells at 5d (mean 6 SD., n=3). The magnification was X 200. Scale bar
represents 10 mm in length. *, P,0.05; ***, P,0.001. (C) 10 nM and 20
nM E2 induced OCT4 expression dramatically in RT-PCR.
doi:10.1371/journal.pone.0028068.g002
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the size and number of mammospheres. The magnification was X 200. Scale bar represents 10 mm in length. (B) Number of mammospheres was
decreased by co-treatment with ICI 182,780. Data were presented as the number of mammospheres per 1,000 seeded cells at 5d (mean 6 S.D., n=3).
**, P,0.01; ***, P,0.001. (C) 100 nM ICI 182,780 could repress the OCT4 induction by 10 nM E2. (D) Immunocytochemical detection of OCT4 in MCF-7
mammospheres, compared to the non-treated control group (Control), 10 nM E2-treated (E2), and 100 nM ICI 182,780 with 10 nM E2 (E2 + ICI). The
magnification was X 200. Scale bar represents 10 mm in length.
doi:10.1371/journal.pone.0028068.g003
Figure 4. Indirect pathways of E2 on MCF-7 mammosphere proliferation. (A) ROS detection with DCF-DA. MCF-7 mammospheres treated
with 10 nM E2 (left), 100 nM E2 (center), or in concert with 10 mM NAC for 7d (right). The magnification was X 200. Scale bar represents 10 mmi n
length. (B) The change of mammosphere number by co-treatment with 10 mM NAC. Results were expressed as the number of mammospheres per
1,000 seeded cells at 5d (mean 6 SD, n=3). (C) Secondary MCF-7 mammospheres treated with 100 nM E2 (upper panels) in concert with 10 mM NAC
(lower panels). The original magnifications were X 200 except left panel of (C) (X 100). Scale bar represents 10 mm in length.
doi:10.1371/journal.pone.0028068.g004
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regulation. E2 and TCDD showed increased biding of ER on
OCT4 promoter, however, BPA did not. The treatment of
metformin decreased binding of ER on OCT4 promoter in E2 or
TCDD treated cells.
Discussion
Our studies were designed to determine if there might be a
biological, non-cytotoxic mechanism to explain several epidemi-
ological and experimental in vitro and in vivo studies, suggesting
an anti-cancer effect of metformin. By using human breast cancer
cell lines, with and without the estrogen receptor, grown in 3-
dimension to try to mimic some in vivo conditions, we show that
several known growth promoters or endocrine disruptors, 17-beta
estradiol, phenol red, TCDD, and bisphenol A, did stimulate
human breast cancer stem cells, as evidenced by both the number
and sizes of MCF-7 mammospheres with the estrogen receptor
and that metformin could suppress this stimulated MCF-7 cancer
stem cell growth at non-cytotoxic concentrations.
The major findings of our studies demonstrated that (a) the 3-
dimensional mammospheres could be used to detect both agents
that stimulated or inhibited the numbers and growth of these
estrogen receptor- positive human breast carcinoma cells; (b) that
17-beta estradiol, and the endocrine disruptors, phenol red,
TCDD, bisphenol A, stimulated both the numbers and growth of
the MCF-7 cancer stem cells; (c) that metformin could inhibit the
mitogenic stimulus of estrogen and the endrocrine disruptors at
non-cytotoxic concentrations; (d) that at low concentrations,
estrogen stimulated the growth of the mammospheres, probably
by an estrogen-dependent mitogenic signaling mechanism,
whereas at higher concentrations, growth inhibition occurred,
probably by some estrogen receptor -independent oxidative stress-
induced mechanism, that blocked the estrogen-dependent signal-
ing; (e) estrogen signaling increased OCT4 expression, while
metformin interrupted estrogen-induced OCT4 expression; and (f)
the mechanism by which bisphenol A enhanced MCF-7 cancer
stem cell self-renewal, as evidenced by mammosphere numbers
and growth were different than the mechanisms by which estrogen
and TCDD worked.
One of the markers used to monitor the effect of both the
estrogen and estrogenic-like compounds, as well as the effect of
metformin, was the OCT4 gene. The OCT4 gene is a member of
POU family and functions as a transcription factor [34]. This gene
is expressed in embryonic stem (ES) cells, germ cells [35], and
adult human stem cells [36], while it helps to maintain an
undifferentiated state and to prevent differentiation [37,38]. In this
study, we showed that OCT4 expression can be induced by 10 nM
17-beta-estradiol in MCF-7 mammospheres. Usually estrogens act
through two kinds of pathways, namely, an estrogen receptor-
dependent pathway and an estrogen receptor-independent
pathway in the cells [39].
Estrogens bind to the estrogen receptor of the nucleus to form
ER-estrogen complexes in the ER-dependent pathway. These
complexes might affect, directly, OCT4 expression by binding to
the OCT4 gene promoter region, thereby, activating gene
transcription. ER-estrogen complexes might also affect, indirectly,
OCT4 expression in relation to histone stability of OCT4 gene
promoter. When ER-estrogen complexes bind to the estrogen
responsive element (ERE) of target genes, p160 and p300 are
recruited to the ER-estrogen complexes and then the PBP/
TRAP220/DRIP205 subunit interacts with complexes [40]. As
Figure 5. Regulation of MCF-7 mammosphere formation by breast cancer promoters and metformin. (A) TCDD increased proliferation
of MCF-7 cells in a dose responsive manner (upper), however, BPA did not (middle). On the other hand, metformin treatment decreased MCF-7
proliferation (mean 6 SD, n=3). *, P,0.05; **, P,0.01; ***, P,0.001. (B, C) Metformin further decreased the size (B) and the number (C) of MCF-7
mammosphere formation enhanced by E2, TCDD or BPA (mean 6 SD, n=3). The magnification was X 200. Scale bar represents 50 mm in length. *,
P,0.05; **, P,0.01; ***, P,0.001.
doi:10.1371/journal.pone.0028068.g005
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region could be exposed to other transcription factors, thereby,
inducing OCT4 promoter activation. On the other hand, in the
ER-independent pathway, estrogens might be metabolized to
metabolites in cytoplasm. As a result, ROS are created. These
ROS are the cause of oxidative stress. ROS induction of various
intra-cellular signal transductors, for example, NF-kB, might be
activated through this pathway [41]. Activated NF-kB could lead
to histone deacetylase (HDAC) activation, inhibiting OCT4 gene
transcription. Recently, Itoh et al. reported that estrogen could
dissociate physical incorporation of ER and HDAC2 which, in
turn, could increase accessibility of ER-estrogen complex to
promoter region of target genes [42]. Moreover, they reported that
treatment of E2 increased transcriptional activity of Sp1, Sp3
transcription factors against GC- rich Sp1, Sp3 site in IL-1a
promoter region. Given that Sp sites are also present in OCT4
promoter region [43], it is reasonable to speculate that estrogen
might affect OCT4 gene transcription directly, or indirectly.
In this study, 17-beta-estradiol (E2) might affect OCT4
expression through both pathways. In low concentrations, up to
20nM E2, the ER-dependent pathway might be activated to
increase the OCT4 expression and a mitogenic response. On the
other hand, ROS production might be increased through an ER-
independent pathway rather than the ER-dependent mechanism
in high concentration 100 nM. The oxidative stress-induced
signaling could inhibit the mitogenic signals of the estrogen-
dependent pathway. Indeed, repression of OCT4 expression in
mammosphere treated with high concentration of E2 was seen.
This suggests that ROS production, induced by 17-beta-estradiol
metabolism, suppressed OCT4 expression.
This dramatic increased expression of the OCT4 after exposure
of these cancer stem cells in mammospheres to estrogen suggests
that estrogen stimulated the symmetrical cell proliferation of
MCF-7 breast cancer stem cells. If this interpretation is correct, it
becomes obvious that a potential human in vitro assay, using 3-
dimenisional MCF-7 mammosphere culture, could be developed
to screen for breast tumor promoters that might mimic what
estrogen does to increase the expression of the OCT4 gene and
lead to human breast cancer.
The normal human breast stem cell expresses OCT4, does not
express connexin43, and expresses the estrogen receptor, as well as
other markers [44,45], similar to the MCF-7 cells. Therefore, in
order to ‘‘target’’ the human breast ‘‘cancer stem cells’’, one must
design new chemopreventive and therapeutic strategies that will
affect the expression of the (a) OCT4 (a gene needed to maintain
the ‘‘stemness’’ of both the normal breast and breast ‘‘cancer’’
stem cells) and (b) connexin 43 gene (a gene required for allowing
differentiation to occur in the normal human breast stem cells).
Rather than trying to ‘‘kill’’ tumor cells or even the ‘‘cancer stem
cells’’, altering the expression of these two genes could induce these
‘‘cancer stem cells’’ to terminally differentiate. However, up until
now, there has been no systematic approach to screen for agents
that might directly affect the OCT4 and connexin 43 genes, with the
possible exception of the study with SAH [46]. Therefore,
suspected human breast ‘‘carcinogens’’ could be detected by an
increase of the expression of OCT4 and estrogen receptor in the
Figure 6. Regulation of OCT4 expression by metformin in MCF-7 cells. (A) E2 and TCDD increases OCT4 expression levels in MCF-7 cell line,
however, BPA did not (mean 6 SD, n=3). **, P,0.01; ***, P,0.001. (B) Schematics of primer design for chromatin immunoprecipitation to detect
putative ERE sequences in OCT4 promoter regions. Arrow heads indicate locations of putative ERE sequences. DE, distal enhancer; PE, proximal
enhancer; PP, proximal promoter. (C) Chromatin immunoprecipitation to assess ER alpha binding at putative ERE sequences in OCT4 promoter region
suggested that a putative ERE sequence at -3544kb from OCT4 transcription starting site was bound to ER alpha (mean 6 SD, n=3). **, P,0.01; ***,
P,0.001. (D) The ERE sequence at -3544kb was enriched with ER alpha by treatment of E2 and TCDD compared to control and BPA treatment group.
The enrichment was attenuated by co-treatment of metformin (mean 6 SD, n=3). *, P,0.05; **, P,0.01; ***, P,0.001.
doi:10.1371/journal.pone.0028068.g006
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connexin 43.
The results of these studies, based on the use of OCT4 as a
normal or cancer stem cell marker and the three-dimensional
mammospheres, implies many additional basic mechanistic
experiments should be done to understand the biology of breast
cancer stem cells and to screen for human breast tumor promoters
and preventive/therapeutic agents for breast cancer. However,
these studies do provide some mechanistic support for the
epidemiological observations that metformin could be a useful
anti-breast cancer chemopreventive treatment.
Materials and Methods
Cell lines
Human MCF-7 (ERa+,E R b+) and MDA-MB-231 (ERa-,
ERb+) breast carcinoma cells were obtained from American Type
Culture Collection (American Type Culture Collection, Manassas,
VA). The Human SK-BR-3 (ERa-, ERb-) breast cancer cells were
obtained from Korea Cell Line Bank (Korea Cell Line Bank,
Seoul, Korea). Transformation of normal human breast epithelial
cells, Type I HBEC, was achieved by introduction of SV40 DNA
as previously described [44]. The SV40-transformed immortal
Type I HBEC derived cell line (M13SV1) is non-tumorigenic, but
X-ray-radiated M13SV1 cell line (M13SV1 R2) is weakly
tumorigenic and neu oncogene-transfected M13SV1 cell line
(M13SV1 R2N1) is highly tumorigenic [44].
Chemicals
To test estrogen and anti-estrogen effects on MCF-7 mammo-
sphere formation, 17-beta-estradiol (Sigma Chemical Co., Saint
Louis, MO) and potent ER inhibitor ICI182,780 (Sigma
Chemical Co) were used. An antioxidant N-acetyl-L-cysteine
(NAC, Sigma Chemical Co) was used to test whether oxidative
stress caused by high concentration of estrogen affects mammo-
sphere formation. 2,3,7,8,-tetrachlorodibenzo-p-dioxin (TCDD),
bisphenol A (BPA) and metformin were also purchased from
Sigma Chemical Co.
Preparation of Mammospheres
Single cells were plated in ultralow attachment plates (Corning
Costar Corp., Cambridge, MA) at a density of 10,000 viable cells/
ml in primary culture and 1000 cells/ml in subsequent passages.
Cells were grown in a serum-free mammary epithelial basal
medium (MEBM, Cambrex Bio Science Inc, Walkersville, MD),
supplemented with 2% B27 (Invitrogen, Carlsbad, CA), 20 ng/ml
EGF (BD Biosciences, Franklin Lakes, NJ), antibiotic-antimycotic
(100 unit/ml penicillin G sodium, 100 mg/ml streptomycin sulfate
and 0.25 mg/ml amphotericin B) (Invitrogen), 20 mg/ml Genta-
mycin, 1 ng/ml Hydrocortisone, 5 mg/ml Insulin and 100 mM2 -
mercaptoethanol (Invitrogen) in a humidified incubator.
FACS analysis
By using a FACSAria (Becton Dickinson, San Jose, CA), the
expression of a panel of breast cancer stem cell markers was
distinctly evaluated on cells obtained from mammospheres. The
antibodies used were phycoerythrin (PE)-conjugated anti-CD24
and fluorescein isothiocyanate (FITC)-conjugated anti-CD44 (BD
Pharmingen, San Diego, CA). Staining was done according to the
instructions of the manufacturer.
Immunocytochemistry
Mammospheres attached to 4-chamber slides were fixed
immediately in 4% paraformaldehyde and permeabilized 0.4%
Triton X-100 for 20 minutes. Mammospheres were blocked with
10% normal goat serum (Zymed Laboratories Inc, San Francisco,
CA) at 4uC overnight and then incubated with rabbit anti-OCT4
polyclonal antibody (Chemicon, Temecula, CA), followed by
incubation with an Alexafluor 594-labeled goat anti-rabbit IgG
(Invitrogen). Nuclear staining was performed by 49,6-diamidino-2-
phenylindole (DAPI, Sigma Chemical Co.). Images were captured
on a Nikon C1si spectral imaging confocal system (Nikon, Tokyo,
Japan).
Semi-quantitative and real-time quantitative reverse
transcription-polymerase chain reaction (RT-PCR) analysis
Total cellular RNA was extracted from cells by using TRIzol
reagent
TM (Invitrogen). cDNA synthesis was accomplished by
adding the purified RNA and oligo-dT primers to Accupower RT
premix (Bioneer, Daejeon, Korea). PCR was conducted with
Accupower PCR premix (Bioneer). All procedures were done as
described by manufactures. Primers for human OCT4 amplifica-
tion were made based on a literature [47]. Realtime-PCR was
performed by mixing cDNA with Power SYBR Green PCR
Master Mix (Applied Biosystems, Foster City, CA) with an ABI
7500 Realtime-PCR System (Applied Biosystems) according to the
manufacturer’s instructions. Gene expression levels were com-
pared after normalization to endogenous GAPDH. The primer
sequences used in this study are illustrated in Table S1.
MTT cell proliferation assay
The proliferation potential of cells was measured using the
MTT assay, which is based on the ability of live cells to convert
tetrazolium salt into purple formazan. Briefly, cells (1610
4 cells
per well) were seeded in 24-well microplates in 450 ml media. After
48 h, 50 ml MTT stock solution (5 mg/ml, Sigma Chemical Co)
was added to each well, and the plates were further incubated for
4 h at 37uC. The supernatant was removed, and 200 ml DMSO
was added to each well to solubilize the water insoluble purple
formazan crystals. The absorbance at a wavelength of 540 nm was
measured with an EL800 microplate reader (BIO-TEK Instru-
ments, Winooski, VT).
ROS detection
ROS detection was performed according to the manufacturer’s
protocol (Invitrogen). Briefly, MCF-7 mammospheres were gently
washed with PBS before staining. After that, the mammospheres
were incubated with 25 mM carboxy-H2DCFDA for 30 min at
37uC, protected from light. Spheres were washed three times with
PBS. Carboxy-DCF was detected by confocal microscope at 495/
529 nm.
ChIP and luciferase reporter assays
ChIP assays were performed according to the manufacturer’s
protocol (Upstate Biotechnology, Waltham, MA). Chromatin was
immunoprecipitated using rabbit anti-human ERa antibodies (sc-
8002, Santacruz). PCR was performed at a final template dilution
of 1:50. The primer sequences used in this study are supplied in
Table S2.
Statistical analysis
The data were expressed as the mean plus or minus the
standard error. Analyses were performed using computerized
statistical software. Statistically significant (P,0.05) data were
further analyzed by Dunnet’s t-tests.
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Figure S1 Cytotoxicity of TCDD, BPA, or metformin.
(A–C) MTT assay for 24 h treatment of TCDD, BPA, or
metformin in MCF-7 cells. Only 100 mM BPA showed cytotoxicity
(mean 6 SD, n=3). ***, P,0.001.
(TIF)
Table S1 Primer sequences used for RT-PCR.
(DOC)
Table S2 Primer sequences used for chromatin immu-
noprecipitation assay for putative estrogen binding
sites.
(DOC)
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